Member Info for ak12345

Anyone know when trials are due to begin?

Let's not forget last month's news about Kinder foundation donating $150 million to MD Anderson and Texas Children's hospital for pediatric cancer.

Thanks for posting. Please keep the updates coming on here as not everyone is on the private telegram group. Will be checking regularly for news

Why is no one posting on here anymore? Don't think this board will be closed

Nasdaq sell off today 4% down, probably had an impact here too

Hopefully this stock can attract the attention of some investment funds now at this market cap. Needs to stay above 100M

I need around $3 to break even, that's about £1 before the consolidation and move to Nasdaq I think

Still no news on this? Been a very long time

Someone previously stated a market cap of 300 million at this stage compared to peers. We only need to 30 bag to get there

Hard to imagine that we were at the equivalent of £28 per share a year ago with FDA approval and now after first infusion and getting trials underway we are at £3.50 a share

Unfortunately shorters are being offered an easy and very cheap exit at this price

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

January 23, 2025 at 3:00 PM EST

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI).

You would think that, but quite a significant dump today

Down 17% today?

This stock really does seem undervalued considering recent news and progress

4.5% dilution for those that don't know. Not anywhere near comparable to MINT

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

November 1, 2024 at 1:00 PM EDT

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.

The BIO-Europe conference provides a prestigious platform for Tiziana to highlight its strategic advancements to the biopharma community, as well as to expand its partnerships aimed at accelerating the development of its therapeutic pipeline. Key representatives from Tiziana will be available for discussions and will share data from our anti-CD3 and Ozempic combination study, which investigates the potential for enhanced therapeutic effects in targeted conditions. This latest clinical update aligns with Tiziana's commitment to advancing therapies that address significant unmet medical needs.

“The BIO-Europe conference offers an ideal opportunity to highlight our latest clinical findings, including the positive data from our GLP-1 combination study,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “We will be engaging with prospective partners in Stockholm to explore collaborations that will further accelerate our mission of delivering groundbreaking therapies to patients worldwide. We look forward to further advancing our Phase 2 studies following on from the closing of a successful fundraise.”

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

30th October 2024

NEW YORK, October 30, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE: NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO), providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction.

Key Highlights:

Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity.

The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

30th October 2024

NEW YORK, October 30, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE: NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO), providing a potential novel approach to combat obesity-related inflammation, and liver inflammation and dysfunction.

Key Highlights:

Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity.

The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.

👍